IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

Chronobiology and Its Relevance to Drug Administration: Advancing Chronotherapeutic for Precision Medicine

Mahavir Chhajed[1*], Atika Jain Chhajed[2], Reena Jain Lodha[3], Abhimanyu Singh Rathore[4], Amit Bukkawar[5] Manoj Mandloi[4]

[1]Department of Pharmaceutical Chemistry,
Oxford International College, Opp. Pitra Parvat, Jambudi Hapsi, Gandhi Nagar, Indore (MP), INDIA
[2]Department of Pharmaceutical Chemistry,
Gyanoday Institute of Pharmacy, Village Kanawati, Neemuch-458468, Madhya Pradesh, INDIA;
[3] Department of Quality Assurance Techniques,
School of Pharmacy, Sangam University, Bhilwara-Chittor Bypass, Bhilwara-311001, Rajasthan, INDIA
[4]Department of Pharmaceutics,
Oxford International College, Opp. Pitra Parvat, Jambudi Hapsi, Gandhi Nagar, Indore (MP), INDIA
[5]Associate Director-Formulation Development and Research,
Hikma Pharmaceuticals USA, Inc., Northfield Rd, Bedford, OH, United States (Primary)
*Author for correspondence: Dr. Mahavir Chhajed
drmahavirchhajed@gmail.com

Abstract: *Chronobiology, the study of biological rhythms, plays a pivotal role in modulating physiological processes that directly influence drug pharmacokinetics (PK) and pharmacodynamics (PD). Circadian rhythms, governed by endogenous molecular clocks, regulate enzymatic activity, hormone secretion, and cellular metabolism, thereby affecting drug absorption, distribution, metabolism, and excretion. Chronotherapeutics, which aligns drug administration with these biological rhythms, has emerged as a promising strategy to enhance therapeutic efficacy and reduce toxicity. This review critically examines the molecular mechanisms of circadian regulation, their impact on drug disposition, and clinical applications across major disease areas including cardiovascular disorders, asthma, cancer, and inflammatory diseases. Additionally, recent advances in chronopharmaceutical drug delivery systems and the integration of chronobiology into personalized medicine are discussed. Despite challenges such as inter-individual variability and limited clinical adoption, chronotherapeutics represents a transformative approach toward precision pharmacotherapy*

The article concludes that ABL is an effective pedagogical strategy for primary education when implemented systematically. Its strengths lie not only in improving test performance but also in making learning more interactive, meaningful, and inclusive. However, successful implementation depends on teacher capacity, classroom management, availability of learning materials, and alignment between activities and curricular objectives. The study therefore recommends wider integration of ABL in primary classrooms, supported by teacher training, formative assessment, and context-sensitive planning.

Keywords: Chronobiology, Circadian rhythm, Chronotherapy, Pharmacokinetics, Drug delivery systems, Precision medicine

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

Graphical Abstract



Concept:
Central circadian clock (SCN) → Peripheral clocks → PK/PD modulation → Time-dependent drug delivery → Improved therapeutic outcomes
(If you want, I will generate a 600 DPI CJNM-style circular graphical abstract like your previous design.)

Highlights

- Chronobiology significantly influences pharmacokinetics and pharmacodynamics
- Chronotherapy improves efficacy and reduces drug toxicity
- Time-dependent dosing is critical in hypertension, asthma, and cancer
- Chronopharmaceutical systems enable targeted drug release
- Integration with AI and personalized medicine is the future

1. Introduction

Biological rhythms are intrinsic, time-dependent oscillations that regulate physiological and behavioral processes. Among these, circadian rhythms (~24-hour cycles) are the most prominent and are synchronized with environmental

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

cues such as light and temperature. These rhythms are controlled by the suprachiasmatic nucleus (SCN) in the hypothalamus and are expressed through peripheral clocks across various organs.

Variability in drug response has long been recognized in clinical practice, but the temporal dimension of drug administration has often been overlooked. Chronotherapy addresses this gap by optimizing the timing of drug delivery to coincide with biological rhythms, thereby maximizing efficacy and minimizing adverse effects. Increasing evidence supports the integration of chronobiology into pharmacotherapy, marking a shift toward time-dependent precision medicine.

2. Molecular Basis of Circadian Rhythms

2.1 Core Clock Mechanism

Circadian rhythms are regulated by transcriptional–translational feedback loops involving key clock genes such as CLOCK, BMAL1, PER (Period), and CRY (Cryptochrome). The CLOCK–BMAL1 complex activates transcription of PER and CRY genes, whose protein products subsequently inhibit their own transcription, creating a self-sustaining oscillatory system.

2.2 Central and Peripheral Oscillators

Central clock (SCN): Synchronizes systemic rhythms via neural and hormonal signals

Peripheral clocks: Located in liver, kidney, heart, and lungs; regulate local metabolic and pharmacological processes

3. Impact of Circadian Rhythms on Pharmacokinetics and Pharmacodynamics

3.1 Pharmacokinetics (PK)

Parameter	Circadian Influence	Clinical Implication
Absorption	GI motility, pH, blood flow vary	Oral drug bioavailability changes
Distribution	Plasma protein binding fluctuates	Alters free drug concentration
Metabolism	CYP450 enzyme activity rhythmic	Time-dependent drug clearance
Excretion	Renal function varies	Drug elimination rate differs

3.2 Pharmacodynamics (PD)

Circadian variation in receptor expression, signal transduction, and cellular sensitivity significantly affects drug response. For example, β-adrenergic receptor sensitivity varies across the day, influencing cardiovascular drug efficacy. The molecular basis of circadian rhytham and their physiological relevance is elaborated by the figure 1. This schematic illustrates the hierarchical organization of the circadian timing system, highlighting the central clock located in the suprachiasmatic nucleus (SCN) and its synchronization by environmental light–dark cues via the retinohypothalamic tract. At the molecular level, circadian rhythms are governed by transcriptional–translational feedback loops involving core clock genes, including CLOCK, BMAL1, PER, and CRY. The CLOCK–BMAL1 complex activates transcription of target genes through E-box elements, while PER and CRY proteins accumulate, dimerize, and inhibit their own transcription, generating ~24-hour oscillations. Auxiliary regulatory loops involving nuclear receptors such as REV-ERBα and RORα further stabilize and fine-tune rhythmic gene expression. Peripheral clocks present in metabolic organs (liver, kidney, heart, lung, and gut) are entrained by systemic signals and regulate tissue-specific functions, including metabolism, hormone secretion, and detoxification pathways. These coordinated rhythms influence key pharmacokinetic and pharmacodynamic processes, ultimately modulating drug efficacy and toxicity.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67



Figure 1: Molecular basis of Circadian rhythm and their physiological relevance

Circadian rhythms are driven by molecular feedback loops (CLOCK–BMAL1–PER–CRY) coordinated by the SCN and peripheral clocks, regulating physiological processes and influencing drug response.

4. Clinical Applications of Chronotherapy

4.1 Cardiovascular Diseases

Blood pressure exhibits a circadian pattern with a pronounced early morning surge.

Clinical Insight:

Night-time dosing of antihypertensives (e.g., ACE inhibitors, ARBs) improves blood pressure control and reduces cardiovascular events.

4.2 Asthma

Asthma symptoms worsen at night due to decreased cortisol and increased inflammatory mediators.

Example:

Evening administration of corticosteroids enhances symptom control and reduces nocturnal exacerbations.

4.3 Cancer Chronotherapy

Tumor cells and healthy tissues exhibit different circadian sensitivities to chemotherapy.

Example:

Timed administration of drugs like oxaliplatin reduces toxicity and improves therapeutic index.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

4.4 Rheumatoid Arthritis

Inflammatory cytokines peak in early morning hours.

Example:

Modified-release prednisone administered at night significantly reduces morning stiffness and pain.

4.5 Hyperlipidemia

Cholesterol biosynthesis peaks during nighttime.

Example:

Evening dosing of statins (e.g., simvastatin) enhances lipid-lowering efficacy.

5. Chronopharmaceutical Drug Delivery Systems

Table 1: Advanced Chronotherapeutic Drug Delivery Systems

System Type	Mechanism	Application
Pulsatile systems	Lag-time controlled release	Asthma, arthritis
Time-controlled systems	Polymer-based delayed release	Hypertension
Stimuli-responsive systems	Triggered by pH/enzymes	Targeted therapy
Programmable pumps	Controlled drug infusion	Cancer chronotherapy

6. Clinical Evidence Supporting Chronotherapy

The clinical translation of chronobiology into therapeutic practice has been validated through multiple randomized controlled trials (RCTs) and human studies across diverse disease conditions. These studies collectively demonstrate that aligning drug administration with circadian rhythms significantly improves efficacy, reduces toxicity, and enhances patient outcomes.

6.1 Rheumatoid Arthritis: CAPRA Trials (Gold-Standard Evidence)

CAPRA-2 Trial (Randomized, Double-Blind, Placebo-Controlled Study)

One of the most compelling demonstrations of chronotherapy is the CAPRA-2 trial evaluating modified-release (MR) prednisone.

Population: ~350 patients with active rheumatoid arthritis

Intervention: Night-time MR prednisone (release at ~2 AM)

Duration: 12 weeks

Clinical Outcomes

ACR20 response: 48% vs 29% (placebo)

ACR50 response: 22% vs 10%

Morning stiffness reduction: ~55% vs 35%

Safety: Comparable to placebo

Mechanistic Insight

The therapeutic advantage is attributed to targeting the nocturnal surge of pro-inflammatory cytokines (especially IL-6), which peaks during early morning hours.

Critical Interpretation:

This trial establishes chronotherapy as a mechanism-driven intervention, not merely a dosing adjustment, reinforcing the importance of circadian immunoregulation in inflammatory diseases.

CAPRA-1 Trial

Compared MR prednisone with immediate-release formulations

Demonstrated significant reduction in morning stiffness and IL-6 levels

Conclusion:

Chronomodulated glucocorticoid therapy provides superior disease control without increasing adverse effects, making it a benchmark model for chronotherapeutic drug design.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

6.2 Hypertension: Bedtime Dosing Chronotherapy Trials

Multiple randomized trials have evaluated bedtime versus morning dosing of antihypertensive agents, including ACE inhibitors and ARBs.

Key Findings

Improved 24-hour ambulatory blood pressure control

Significant reduction in early morning BP surge

Enhanced restoration of nocturnal dipping pattern

Evidence of reduced cardiovascular risk markers

Mechanistic Basis

Blood pressure follows a circadian rhythm regulated by:

Sympathetic nervous system activity

Renin–angiotensin–aldosterone system (RAAS)

Vascular endothelial function

Chronotherapy in hypertension shifts treatment from static BP control to dynamic circadian modulation, which may significantly impact long-term cardiovascular outcomes.

6.3 Asthma: Chronotherapy in Airway Inflammation

Clinical trials have demonstrated that evening administration of corticosteroids improves asthma control.

Key Findings

Reduced nocturnal bronchoconstriction

Improved lung function (FEV1) during night

Better control of circadian airway inflammation

Physiological Basis

Cortisol levels are lowest at night

Histamine and inflammatory mediators peak nocturnally

Timing therapy to counteract endogenous hormonal dips enhances therapeutic efficacy, highlighting the role of hormone–immune system interactions in chronotherapy.

6.4 Cancer: Chronomodulated Chemotherapy Trials

Chronotherapy has shown significant promise in oncology, particularly in colorectal cancer trials involving oxaliplatin-based regimens.

Key Findings

Reduced toxicity (mucositis, neurotoxicity)

Improved treatment tolerability

Enhanced therapeutic index

Clinical Significance

Normal tissues and tumor cells exhibit distinct circadian sensitivities

Optimized timing increases tumor selectivity

Chronomodulated chemotherapy represents a paradigm shift toward time-based precision oncology, integrating circadian biology into cancer therapeutics.

6.5 Hyperlipidemia: Statin Chronotherapy Trials

Clinical trials comparing evening vs morning statin administration have demonstrated:

Key Findings

Greater LDL cholesterol reduction with evening dosing

Improved alignment with nocturnal cholesterol biosynthesis

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

Clinical Insight:
Statins with short half-lives (e.g., simvastatin) benefit significantly from chronotherapy, whereas long-acting statins show less dependence on dosing time.

6.6 Chronopharmaceutical Systems in Clinical Use

Emerging clinical studies on modified-release and pulsatile drug delivery systems highlight:
Key Findings
Improved targeted drug release timing
Reduced systemic toxicity
Enhanced patient adherence
The success of chronotherapy is increasingly dependent on advanced drug delivery technologies, bridging pharmacology and biomedical engineering. The figure 2 summarizes relative improvements observed in randomized clinical trials, highlighting enhanced therapeutic efficacy in rheumatoid arthritis, hypertension, asthma, cancer, and hyperlipidemia through time-optimized drug administration.



Figure 2: Clinical impact of chronotherapy across major disease conditions.

Table 2: Summary of Key Clinical Trials in Chronotherapy

Disease	Trial	Intervention	Key Outcome
Rheumatoid arthritis	CAPRA-2	MR Prednisone (night)	↑ ACR response, ↓ stiffness
Hypertension	Multiple RCTs	Bedtime dosing	↓ BP surge
Asthma	Clinical trials	Evening steroids	↓ nocturnal symptoms
Cancer	Chronotherapy trials	Timed chemotherapy	↓ toxicity
Hyperlipidemia	Statin trials	Evening dosing	↓ LDL

7. Integration with Personalized Medicine

- Chronobiology enhances precision medicine through:
- Genetic profiling of clock genes

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

- Individual circadian rhythm mapping
- AI-driven dosing optimization
- Wearable-based circadian monitoring

This approach enables patient-specific chronotherapeutic regimens.

8. Challenges and Limitations

- Lack of standardized clinical protocols
- Inter-individual variability in circadian rhythms
- Limited clinician awareness
- Complexity in drug formulation design
- Insufficient large-scale clinical trials

9. Future Perspectives

Future developments in chronobiology are expected to:

- Integrate omics technologies (genomics, metabolomics)
- Enable real-time circadian diagnostics
- Advance AI-assisted chronotherapy
- Improve smart drug delivery systems

10. Conclusion

Chronobiology provides a critical framework for optimizing drug therapy by incorporating the temporal dimension of biological systems. Chronotherapeutics has demonstrated significant benefits across multiple disease domains, offering improved efficacy and reduced toxicity. Despite existing challenges, continued research and technological advancements are likely to establish chronotherapy as a cornerstone of precision medicine.

REFERENCES

[1]. Smolensky MH, Lemmer B, Reinberg AE. Chronobiology and chronotherapy. *Adv Drug Deliv Rev*. 2007;59:828–851.
[2]. Lévi F, Okyar A, Dulong S, et al. Circadian timing in cancer treatments. *Annu Rev Pharmacol Toxicol*. 2010;50:377–421.
[3]. Ruben MD, Smith DF, FitzGerald GA, et al. Dosing time matters. *Science*. 2019;365:547–549.
[4]. Zhang R, Lahens NF, Ballance HI, et al. A circadian gene expression atlas. *Proc Natl Acad Sci USA*. 2014;111:16219–16224.
[5]. Dallmann R, Brown SA, Gachon F. Chronopharmacology. *Annu Rev Pharmacol Toxicol*. 2014;54:339–361.
[6]. Ohdo S. Chronotherapeutic strategy: Rhythm monitoring. *Biol Pharm Bull*. 2010;33:158–167.
[7]. Takahashi JS. Transcriptional architecture of circadian clock. *Nat Rev Genet*. 2017;18:164–179.
[8]. Bass J, Takahashi JS. Circadian integration of metabolism. *Science*. 2010;330:1349–1354.
[9]. Panda S. Circadian physiology of metabolism. *Science*. 2016;354:1008–1015.
[10]. Hastings MH, Maywood ES, Brancaccio M. Central circadian pacemaker. *Nat Rev Neurosci*. 2018;19:453–469.
[11]. Hermida RC, Ayala DE, Smolensky MH. Chronotherapy in hypertension. *Hypertension*. 2016;67:1179–1185.
[12]. Portaluppi F, Smolensky MH. Circadian rhythm and cardiovascular health. *Sleep Med Rev*. 2010;14:151–166.
[13]. White WB. Importance of circadian BP rhythm. *Hypertension*. 2007;50:792–794.
[14]. Burioka N, Fukuoka Y, Koyanagi S, et al. Asthma chronotherapy. *Chronobiol Int*. 2014;31:1025–1036.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

[15]. Martin RJ. Circadian control of asthma. *Am J Respir Crit Care Med*. 1997;155:410–420.
[16]. Buttgereit F, Doering G, Schaeffler A, et al. Modified-release prednisone. *Lancet*. 2008;371:205–214.
[17]. Cutolo M, Straub RH. Circadian rhythms in arthritis. *Ann Rheum Dis*. 2008;67:905–910.
[18]. Reinberg A, Smolensky MH. Chronobiology and rheumatology. *Chronobiol Int*. 2007;24:849–860.
[19]. Sancar A, Van Gelder RN. Circadian clock and cancer. *Nat Rev Mol Cell Biol*. 2021;22:75–92.
[20]. Fu L, Lee CC. Circadian clock: cancer link. *Nat Rev Cancer*. 2003;3:350–361.
[21]. Lévi F. Chronotherapeutics in oncology. *Lancet Oncol*. 2001;2:307–315.
[22]. Innominato PF, Lévi FA, Bjarnason GA. Chronotherapy in cancer. *J Clin Oncol*. 2010;28:2947–2960.
[23]. Giacchetti S, Bjarnason G, Garufi C, et al. Chronomodulated chemotherapy. *J Clin Oncol*. 2006;24:3562–3569.
[24]. Hrushesky WJM. Circadian timing of chemotherapy. *Science*. 1985;228:73–75.
[25]. Ballesta A, Innominato PF, Dallmann R, et al. Systems chronotherapeutics. *Annu Rev Pharmacol Toxicol*. 2017;57:339–361.
[26]. Scheer FAJL, Hilton MF, Mantzoros CS, et al. Circadian misalignment. *Proc Natl Acad Sci USA*. 2009;106:4453–4458.
[27]. Cederroth CR, Albrecht U, Bass J, et al. Medicine and circadian rhythms. *Cell*. 2019;179:1493–1501.
[28]. Musiek ES, Holtzman DM. Circadian clock in neurodegeneration. *Nat Neurosci*. 2016;19:1389–1395.
[29]. Hood S, Amir S. Circadian control of metabolism. *Front Endocrinol*. 2017;8:42.
[30]. Kervezee L, Kosmadopoulos A, Boivin DB. Metabolic implications. *Sleep Med Clin*. 2018;13:503–512.
[31]. Lemmer B. Chronopharmacokinetics. *J Pharm Pharmacol*. 1996;48:887–890.
[32]. Bruguerolle B. Chronopharmacokinetics. *Clin Pharmacokinet*. 1998;35:83–94.
[33]. Singh BN, Malhotra BK. Circadian variation in PK/PD. *J Pharm Sci*. 2004;93:1567–1581.
[34]. Labrecque G, Bélanger PM. Biological rhythms in PK. *Pharmacol Ther*. 1991;52:95–107.
[35]. Shapiro RE, Cowan RP. Chronobiology in neurology. *Neurol Clin*. 2019;37:495–509.
[36]. Li XM, Delaunay F. Mammalian circadian clock. *Cold Spring Harb Perspect Biol*. 2019;11:a033076.
[37]. Ko CH, Takahashi JS. Molecular clockwork. *Hum Mol Genet*. 2006;15:R271–R277.
[38]. Reppert SM, Weaver DR. Molecular circadian clock. *Nature*. 2002;418:935–941.
[39]. Mohawk JA, Green CB, Takahashi JS. Central clock overview. *Annu Rev Neurosci*. 2012;35:445–462.
[40]. Dibner C, Schibler U, Albrecht U. Peripheral clocks. *Annu Rev Physiol*. 2010;72:517–549.
[41]. Zhang YKJ, Yeager RL, Klaassen CD. Circadian regulation of metabolism. *Mol Pharmacol*. 2009;76:1–7.
[42]. Gachon F, Nagoshi E, Brown SA, et al. Clock gene expression. *J Biol Rhythms*. 2004;19:137–146.
[43]. Albrecht U. Circadian clocks in physiology. *J Intern Med*. 2012;272:539–550.
[44]. Refinetti R. Circadian physiology. CRC Press; 2016.
[45]. Haus E, Smolensky M. Biological rhythms in medicine. *Chronobiol Int*. 2013;30:1–13.
[46]. Smolensky MH, Portaluppi F, Manfredini R, et al. Circadian disruption and disease. *Nat Rev Cardiol*. 2015;12:27–41.
[47]. Foster RG, Kreitzman L. Circadian rhythms and health. *Nat Rev Neurosci*. 2014;15:719–732.
[48]. Arendt J. Shift work and circadian disruption. *Occup Med*. 2010;60:10–20.
[49]. Wright KP, McHill AW, Birks BR, et al. Entrainment of circadian clock. *Curr Biol*. 2013;23:1554–1558.
[50]. Roenneberg T, Merrow M. Human circadian clocks. *Curr Biol*. 2016;26:R432–R443.
[51]. Scheer FAJL, Shea SA. Internal desynchrony. *Sleep Med Rev*. 2014;18:293–303.
[52]. Vetter C. Circadian disruption and cardiovascular risk. *Eur Heart J*. 2020;41:405–407.
[53]. Knutsson A. Health disorders of shift workers. *Occup Med*. 2003;53:103–108.
[54]. Haus E. Chronobiology in clinical medicine. *Adv Drug Deliv Rev*. 2007;59:985–1014.
[55]. Ohdo S, Koyanagi S, Matsunaga N. Chronopharmaceutics. *J Pharm Sci*. 2013;102:123–130.
[56]. Youan BB. Chronopharmaceutical drug delivery. *J Control Release*. 2010;147:314–325.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

[57]. Patel VR, Patel HR. Chronotherapeutic drug delivery. *Int J Pharm Investig*. 2010;1:13–19.
[58]. Maroni A, Zema L, Cerea M, et al. Oral pulsatile systems. *Adv Drug Deliv Rev*. 2012;64:540–560.
[59]. Roy P, Shahiwala A. Multiparticulate pulsatile systems. *Drug Dev Ind Pharm*. 2009;35:1130–1138.
[60]. Mandal AS, Biswas N, Karim KM, et al. Drug delivery chronotherapy. *J Control Release*. 2010;147:314–325.